Bristol Myers Squibb (BMY) announced that the FDA has granted accelerated approval to the label expansion of chimeric antigen receptor (CAR) T cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel).The regulatory body approved Breyanzi for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approv ...

Bristol-Myers Squibb Company (NYSE:BMY) Bank of America Global Healthcare Conference 2024 May 15, 2024 2:20 PM ET Company Participants David Elkins – Executive Vice President and Chief Financial Officer Conference Call Participants Geoff Meacham – Bank of America Chen Yang – Bank of America Geoff Meacham I’m Geoff Meacham. I’m the senior biopharma analyst, and I have Charlie from my team on stage with me as well. Welcome to the Bristol-Myers session. So on behalf of Bristol, we have CFO, David Elkins. David ...

Bristol-Myers Squibb Company (NYSE:BMY) Bank of America Global Healthcare Conference 2024 May 15, 2024 2:20 PM ET Company Participants David Elkins – Executive Vice President and Chief Financial Officer Conference Call Participants Geoff Meacham – Bank of America Chen Yang – Bank of America Geoff Meacham I’m Geoff Meacham. I’m the senior biopharma analyst, and I have Charlie from my team on stage with me as well. Welcome to the Bristol-Myers session. So on behalf of Bristol, we have CFO, David Elkins. David ...

Give someone a dividend and you pay them that day but teach them to capture the dividend and you provide investment income for life!Executing a capture-the-dividend trade entails buying the stock before the ex-date so you are the shareholder of record. You then sell it to book the dividend income, making little if any capital gains (that would be nice but it is not the objective). There are many factors to consider in buying dividend stocks for tactical traders.  The bigger the dividend the bigger the profi ...

Bristol-Myers Squibb Company. (NYSE:BMY) Guggenheim Securities Radiopharmaceuticals Day May 13, 2024 11:00 AM ET Company Participants Ben Hickey - President RayzeBio, Head of Mirati Conference Call Participants Unidentified Analyst Alright, Ben, let's continue here with Ben Hickey now from Bristol. Welcome. Thanks for joining us today. And so, yes, before we start with the fireside chat here, yes could you just introduce yourself and talk a bit about your role at Bristol. First of all, good to see you. Ben ...

Summary of Bristol-Myers Squibb Company Conference Call Company Overview - **Company**: Bristol-Myers Squibb Company (NYSE: BMY) - **Event**: Guggenheim Securities Radiopharmaceuticals Day - **Date**: May 13, 2024 Key Points Acquisition of RayzeBio - **Strategic Importance**: The acquisition of RayzeBio aligns with Bristol's focus on oncology, particularly in the radiotherapy space, which is seen as the next wave of cancer treatment [4][8] - **Operational Structure**: RayzeBio will operate as an independent entity within Bristol, allowing for agile decision-making akin to a biotech while leveraging Bristol's resources [6][4] - **Market Timing**: The acquisition was driven by the growing interest and potential in the radiotherapy market, making it an opportune moment for Bristol to enhance its capabilities [8] Technology and Product Development - **Actinium-225 Technology**: Bristol views actinium-based technology as superior due to its potency and ability to create double DNA strand breaks, which may lead to better patient outcomes [10][11] - **Clinical Trials**: The Phase 3 trial for RZY101 is designed as a post-lutetium study, with a focus on progression-free survival (PFS) as the primary endpoint [13][12] - **Safety Profile**: Early data indicates a favorable safety profile for RZY101, with minimal concerns regarding kidney accumulation [17] Pipeline and Future Opportunities - **Small Cell Lung Cancer**: RZY101 is being evaluated in combination with standard-of-care treatments, targeting a significant unmet need in this area [21][23] - **Hepatocellular Carcinoma (HCC)**: The GPC3 program aims to address the high unmet need in HCC, with plans to file an IND in the second half of 2024 [27][30] - **Expansion Plans**: Bristol is actively looking to expand its pipeline in radiotherapeutics, with a focus on both internal development and potential collaborations [39][40] Manufacturing and Supply Chain - **In-House Manufacturing**: Bristol has established a new facility in Indianapolis to ensure a reliable supply of actinium, addressing sourcing challenges in the market [33][32] - **Logistics Strategy**: The company is implementing systems for just-in-time delivery of therapies, leveraging its global footprint to meet patient needs efficiently [35] Financial Considerations - **Cost of Goods Sold (COGS)**: While specific guidance on COGS was not provided, it is expected to be within a similar range to existing lutetium-based programs, with potential for improvement as in-house capabilities expand [37] Conclusion - **Commitment to Oncology**: Bristol-Myers Squibb is positioning itself as a leader in the radiotherapy space, with a strong focus on innovation, strategic acquisitions, and expanding its clinical pipeline to address significant unmet medical needs in oncology [40][39]

Bristol Myers (BMY) recently announced that a late-stage study, seeking to expand the label of its cancer combination drug, Opdivo (nivolumab) and Yervoy (ipilimumab), failed to meet the primary endpoint of progression-free survival in unresectable, locally advanced stage III non-small cell lung cancer (NSCLC).The phase III CheckMate -73L study evaluated Opdivo with concurrent chemoradiotherapy (CCRT) followed by Opdivo plus Yervoycompared with CCRT followed by AstraZeneca’s (AZN) Imfinzi (durvalumab) in 92 ...

Bad news can be good news for an enterprising investor with a longer time horizon than the market's immediate reaction.About once every 90 days, publicly traded companies have to face their shareholders and let them know how their businesses have performed over the past quarter. Those earnings releases often bring with them all sorts of news that can move the market.Sometimes that news is bad, which can knock a company's stock down. Yet that can provide an opportunity for investors to buy shares at a bargai ...

Should investors brace for a dividend cut?Bristol Myers Squibb (BMY 0.45%) pays investors an attractive dividend, which yields an incredibly high rate of 5.5%. That's nearly four times the S&P 500 average of 1.4%. At such a high rate, investing approximately $18,200 would be enough to generate $1,000 in annual dividends from the stock.However, as is the case with many high-yielding stocks, Bristol Myers' dividend comes with some risk. The company's growth has been a concern for investors, and recently, its ...

Key PointsA dismal report from CVS has sent shares plunging, but they already look to have put in a low. Bristol-Myers is experiencing something similar, with a big day of gains yesterday boding well for next week. TripAdvisor shares are still recovering from Wednesday's shock and hold the most risk but also the most reward. 5 stocks we like better than CVS HealthSavvy stock investors often look for bargains using the Relative Strength Index (RSI). This technical tool evaluates a stock's performance over th ...